AlloVir Q2 net loss $44.6M; $126.5M July offering extends cash runway for Phase 3 trials

Kalaris Therapeutics, Inc.

2022-Q2 EPS reported -$1.38

Net loss $44.6M ($0.69/sh) vs $37.6M ($0.60/sh) in Q2 2021; R&D expense rose to $31.4M.
Cash $172.7M at June 30; July registered direct offering raised $126.5M to fund three Phase 3 posoleucel trials.
Phase 2 multi-virus prevention final data expected year-end; Phase 2 BKV treatment topline in Q1 2023.
Posoleucel granted EMA orphan designation for prevention; now holds three FDA RMAT designations.
FY2022 operating expense guidance $130-145M, excluding stock-based compensation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.